QCM Cayman’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

QCM Cayman’s Portfolio LABU Stock Details LABU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-592	Closed	-$70.1K	–	89
2023 Q2	$70.1K	Buy	+592	New	+$73.8K	0.41%	54

Other funds holding LABU

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

QCM Cayman's LABU Position: Q3 2023 in Review

QCM Cayman sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q3 2023, closing a stake of 592 shares — an estimated $70.1K sold.

QCM Cayman first reported a position in LABU in Q2 2023 and held it in 1 quarter. The position peaked at $70.1K in Q2 2023. 47 funds tracked by Wall St. Rank hold LABU as of Q3 2023.

QCM Cayman reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q3 2023 after selling out during the quarter.
QCM Cayman sold 592 Direxion Daily S&P Biotech Bull 3X ETF shares in Q3 2023, an estimated $70.1K.
QCM Cayman first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q2 2023 and held it in 1 quarter.
QCM Cayman's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $70.1K in Q2 2023.
47 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q3 2023.

Based on QCM Cayman's 13F filing for Q3 2023, filed 30 Oct 2023.